DOP2023000271A - Derivados de la urea que pueden ser utilizados para tratar el cáncer - Google Patents

Derivados de la urea que pueden ser utilizados para tratar el cáncer

Info

Publication number
DOP2023000271A
DOP2023000271A DO2023000271A DO2023000271A DOP2023000271A DO P2023000271 A DOP2023000271 A DO P2023000271A DO 2023000271 A DO2023000271 A DO 2023000271A DO 2023000271 A DO2023000271 A DO 2023000271A DO P2023000271 A DOP2023000271 A DO P2023000271A
Authority
DO
Dominican Republic
Prior art keywords
treat cancer
urea derivatives
pi3ka
disorder
disease
Prior art date
Application number
DO2023000271A
Other languages
English (en)
Spanish (es)
Inventor
St Jean David Jr
David Cummings Maxwell
Original Assignee
Scorpion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics Inc filed Critical Scorpion Therapeutics Inc
Publication of DOP2023000271A publication Critical patent/DOP2023000271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Iron (AREA)
  • Catalysts (AREA)
DO2023000271A 2021-06-14 2023-12-13 Derivados de la urea que pueden ser utilizados para tratar el cáncer DOP2023000271A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163210370P 2021-06-14 2021-06-14
US202163228351P 2021-08-02 2021-08-02
US202163288909P 2021-12-13 2021-12-13
US202263316017P 2022-03-03 2022-03-03
US202263319236P 2022-03-11 2022-03-11
US202263348261P 2022-06-02 2022-06-02
PCT/US2022/033255 WO2022265993A1 (en) 2021-06-14 2022-06-13 Urea derivatives which can be used to treat cancer

Publications (1)

Publication Number Publication Date
DOP2023000271A true DOP2023000271A (es) 2024-03-28

Family

ID=82403494

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000271A DOP2023000271A (es) 2021-06-14 2023-12-13 Derivados de la urea que pueden ser utilizados para tratar el cáncer

Country Status (22)

Country Link
US (5) US20240300939A1 (https=)
EP (1) EP4334298B1 (https=)
JP (2) JP7728367B2 (https=)
KR (1) KR20240035395A (https=)
AU (1) AU2022292554A1 (https=)
CA (1) CA3220039A1 (https=)
CL (1) CL2023003691A1 (https=)
CO (1) CO2023017150A2 (https=)
CR (1) CR20230576A (https=)
DO (1) DOP2023000271A (https=)
EC (1) ECSP23093675A (https=)
FI (1) FI4334298T3 (https=)
IL (1) IL309232A (https=)
JO (1) JOP20230320A1 (https=)
MA (1) MA63501B1 (https=)
MX (1) MX2023014819A (https=)
PE (1) PE20250155A1 (https=)
TN (1) TN2023000286A1 (https=)
TW (1) TW202317526A (https=)
UA (1) UA130639C2 (https=)
WO (1) WO2022265993A1 (https=)
ZA (1) ZA202311329B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
WO2023220131A2 (en) * 2022-05-10 2023-11-16 Relay Therapeutics, Inc. PI3Kα INHIBITORS AND METHODS OF USE THEREOF
CN120500480A (zh) * 2022-10-07 2025-08-15 蝎子疗法股份有限公司 治疗癌症的方法
CN120529906A (zh) * 2022-10-31 2025-08-22 蝎子疗法股份有限公司 用于治疗癌症的组合疗法
TW202541794A (zh) * 2022-11-02 2025-11-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點
CN120265618A (zh) * 2023-03-31 2025-07-04 长春金赛药业有限责任公司 PI3Kα抑制剂化合物、药物组合物及其应用
WO2024222894A1 (en) * 2023-04-27 2024-10-31 Laekna Pharmaceutical Ningbo Co., Ltd. Benzofuran compounds and their use as pi3k alpha inhibitors
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
WO2025002179A1 (en) * 2023-06-27 2025-01-02 Laekna Pharmaceutical Ningbo Co., Ltd. Heterotricyclic n-[1-(2-benzofuranyl)-methyl]-urea derivatives as pi3k alpha inhibitors for the treatment of cancer
TW202508560A (zh) 2023-08-15 2025-03-01 美商史考皮恩治療有限公司 製備ｐ１３ｋ抑制劑之方法
IL326463A (en) 2023-08-15 2026-04-01 Scorpion Therapeutics Inc Crystalline forms of PI3K inhibitor and its uses
TW202600543A (zh) * 2024-03-11 2026-01-01 大陸商長春金賽藥業有限責任公司 ＰＩ３Ｋα抑制劑化合物、藥物組合物及其用途
WO2025231327A1 (en) * 2024-05-03 2025-11-06 Scorpion Therapeutics, Inc. Pi3k degraders and methods of using same
TW202547511A (zh) 2024-05-30 2025-12-16 大陸商來凱製藥（寧波）有限公司 雜芳基化合物及其用作ＰＩ３Ｋα抑制劑之用途
WO2025264581A1 (en) * 2024-06-17 2025-12-26 Leapfrog Bio, Inc. P110 inhibitors for the treatment of cancer

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US4735941A (en) 1986-12-23 1988-04-05 Merck & Co., Inc. 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents
EP0304223A3 (en) 1987-08-17 1990-10-24 Merck & Co. Inc. Beta-carbolines as cholecy-stokinin and gastrin antagonist
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5032604A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
CA2032427A1 (en) 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepines analogs
CA2032226A1 (en) 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepine analogs
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
CA2056809A1 (en) 1990-12-07 1992-06-08 Mark G. Bock Benzodiazepine analogs
US5206237A (en) 1991-05-14 1993-04-27 Merck & Co., Inc. Benzodiazepine analogs
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
EP0518484A3 (en) 1991-05-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
CA2071092A1 (en) 1991-06-14 1992-12-15 Roger M. Freidinger 1,4-benzodiazepines with 5-membered heterocyclic rings
EP0523845A3 (en) 1991-06-14 1993-11-18 Merck & Co Inc New benzodiazepine analogs
US5177071A (en) 1991-06-17 1993-01-05 Merck & Co., Inc. 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
AU4028393A (en) 1992-05-28 1993-12-30 Pfizer Inc. New (N)-aryl and (N)-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (ACAT)
ATE188379T1 (de) 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
FR2725985B1 (fr) 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2734814B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0862436A1 (en) 1995-10-19 1998-09-09 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5821261A (en) 1995-12-08 1998-10-13 Merck & Co., Inc. Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase
DE69732868T2 (de) 1996-11-25 2006-04-13 Toray Industries, Inc. Mittel gegen Juckreiz
AU7080298A (en) 1997-04-25 1998-11-24 Takeda Chemical Industries Ltd. Triazine derivatives, their production and agrochemical composition
PT948965E (pt) 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
WO1999005146A1 (en) 1997-07-25 1999-02-04 Toray Industries, Inc. Hyponatremia remedies
JP4359711B2 (ja) 1997-09-02 2009-11-04 東レ株式会社 薬物依存症治療薬
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
EP1115731A2 (de) 1998-09-04 2001-07-18 Byk Gulden Lomberg Chemische Fabrik GmbH Neue pyranosen
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
DE69926806D1 (de) 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
CN1204139C (zh) 1999-08-24 2005-06-01 东丽株式会社 神经性疼痛治疗剂
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
CA2397575A1 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6545152B1 (en) 2000-07-18 2003-04-08 Parker Hughes Institute R-isomers of nonnucleoside inhibitors
US8338442B2 (en) 2001-03-30 2012-12-25 Toray Industries, Inc. Remedies for psychoneurosis
JP4239592B2 (ja) 2001-05-08 2009-03-18 東レ株式会社 敗血症治療剤
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
MY130373A (en) 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
MXPA04010539A (es) 2002-04-26 2005-01-25 Nippon Shinyaku Co Ltd Derivados de quinazolina y medicamentos que los contienen.
US20050203084A1 (en) 2002-05-22 2005-09-15 Jeong Jae U. Protease inhibitors
WO2004007459A2 (en) 2002-07-12 2004-01-22 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
JP2004083511A (ja) 2002-08-28 2004-03-18 Yamanouchi Pharmaceut Co Ltd アクリルアミド誘導体
AU2003261756A1 (en) 2002-08-28 2004-03-29 Toray Industries, Inc. Acrylamide derivatives
CA2527934A1 (en) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc Tetrazol benzofurancarboxamides with p13k activity as therapeutic agents
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
CA2536253A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
CA2542220A1 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
AU2004285053B2 (en) 2003-10-28 2010-10-21 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
CA2544857A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
ES2351665T3 (es) 2005-03-24 2011-02-09 Rottapharm S.P.A. Derivados de benzamidina para el tratamiento y la prevención de mucositis.
MX2007015726A (es) 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
WO2007026720A1 (ja) 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
EP1934191B1 (en) 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
EP2316829A1 (en) 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
AU2007227274A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1P receptor modulating compounds
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
EP2051964A4 (en) 2006-07-28 2012-03-07 Univ Connecticut INHIBITORS OF FATTY ACID AMIDHYDROLASE
WO2008027483A1 (en) 2006-08-31 2008-03-06 Arena Pharmaceuticals, Inc. Benzofuran derivatives as modulators of the 5-ht2a receptor
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
PL2151240T3 (pl) 2007-04-24 2014-01-31 Toray Industries Środek terapeutyczny lub profilaktyczny przeciw dyskinezie
PT2151241E (pt) 2007-04-26 2012-05-07 Toray Industries Preparação sólida estável compreendendo um derivado de 4,5-epoximorfinano
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
CA2690410C (en) 2007-06-12 2015-09-29 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
PL2196206T3 (pl) 2007-10-05 2020-02-28 Toray Industries, Inc. Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
CN101412692B (zh) 2007-10-18 2012-10-17 中国科学院上海药物研究所 1-(3-氨基丙基)哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MX2010007548A (es) 2008-01-11 2010-11-25 Univ California Activadores de procaspasas 3, 6 y 7 efectoras.
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
JP2011520809A (ja) 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
TWI392673B (zh) 2008-08-27 2013-04-11 Calcimedica Inc 調控細胞內鈣離子濃度之化合物
CN101712679B (zh) 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
CA2740476C (en) 2008-10-24 2016-04-05 Toray Industries, Inc. Stable tablet containing 4,5-epoxymorphinan derivative
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
IN2012DN01983A (https=) 2009-08-24 2015-07-24 Ascepion Pharmaceuticals Inc
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
PH12012501552A1 (en) 2010-01-29 2017-04-26 Toray Industries Therapeutic or prophylactic agent for biliary diseases
US20130165475A1 (en) 2010-09-01 2013-06-27 Ascepion Pharmaceuticals, Inc. Deuterium-enriched heterocyclic compounds as kinase inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
CA2825165C (en) 2011-01-31 2018-07-03 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9282738B2 (en) 2011-07-11 2016-03-15 Wisconsin Alumni Research Foundation Antimicrobial compositions and methods of use thereof
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
BR112014015308A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
JP6207399B2 (ja) 2012-01-13 2017-10-04 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
DE102012103405A1 (de) 2012-04-18 2013-10-24 Heinrich-Pette-Institut Desoxyhypusin-Synthase-Inhibitoren
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP3082805B1 (en) 2013-12-20 2020-02-05 Institute for Drug Discovery, LLC Substituted amino triazoles, and methods using same
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
EP2993174A1 (en) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
TWI664166B (zh) 2014-10-24 2019-07-01 日商小野藥品工業股份有限公司 Ｋｃｎｑ２至５通道活化劑
ES2942308T3 (es) 2015-04-21 2023-05-31 Allgenesis Biotherapeutics Inc Compuestos y su uso como inhibidores de BACE1
WO2017039318A1 (en) 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
JP6943239B2 (ja) 2016-04-22 2021-09-29 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル活性化剤
CN109311882B (zh) 2016-05-04 2022-02-11 Bci制药公司 作为蛋白激酶抑制剂的腺嘌呤衍生物
WO2018165501A1 (en) 2017-03-10 2018-09-13 Lycera Corporation INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
WO2019111225A1 (en) 2017-12-08 2019-06-13 Avaliv Therapeutics Compounds and methods for the treatment of non‑alcoholic steatohepatitis
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
WO2020028515A1 (en) 2018-07-31 2020-02-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Neuroprotective disruption of kv2.1/syntaxin interaction by small molecules
TW202021956A (zh) 2018-08-09 2020-06-16 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
EP3841221A4 (en) 2018-08-23 2022-06-08 Memorial Sloan-Kettering Cancer Center BIOMARKERS TO DETERMINE CANCER SENSITIVITY TO PI3K INHIBITORS
JP7541483B2 (ja) 2018-09-03 2024-08-28 日本ケミファ株式会社 糖尿病性末梢神経障害のための医薬
CN111039942B (zh) 2018-10-12 2023-04-14 上海长森药业有限公司 含氮杂环类化合物，及其制备方法、药物组合物和应用
CA3136151A1 (en) 2019-04-12 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
CN112566905B (zh) 2019-05-10 2024-07-30 上海海雁医药科技有限公司 取代的苯基丙烯基吡啶类衍生物，其制法与医药上的用途
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Also Published As

Publication number Publication date
JP2025134924A (ja) 2025-09-17
AU2022292554A1 (en) 2024-01-04
US20240400543A1 (en) 2024-12-05
UA130639C2 (uk) 2026-04-01
US20250250259A1 (en) 2025-08-07
JP2024522192A (ja) 2024-06-11
ECSP23093675A (es) 2024-03-01
ZA202311329B (en) 2025-04-30
EP4334298B1 (en) 2026-02-18
CA3220039A1 (en) 2022-12-22
US20240076289A1 (en) 2024-03-07
FI4334298T3 (fi) 2026-04-30
TW202317526A (zh) 2023-05-01
CO2023017150A2 (es) 2024-05-10
US12084434B2 (en) 2024-09-10
PE20250155A1 (es) 2025-01-22
JOP20230320A1 (ar) 2023-12-10
CR20230576A (es) 2024-04-05
MA63501A1 (fr) 2024-03-29
MA63501B1 (fr) 2024-07-31
US11897871B1 (en) 2024-02-13
IL309232A (en) 2024-02-01
JP7728367B2 (ja) 2025-08-22
EP4334298A1 (en) 2024-03-13
US12312341B2 (en) 2025-05-27
WO2022265993A1 (en) 2022-12-22
US20240158376A1 (en) 2024-05-16
MX2023014819A (es) 2024-03-21
TN2023000286A1 (en) 2025-07-02
CL2023003691A1 (es) 2024-06-07
US20240300939A1 (en) 2024-09-12
KR20240035395A (ko) 2024-03-15

Similar Documents

Publication Publication Date Title
DOP2023000271A (es) Derivados de la urea que pueden ser utilizados para tratar el cáncer
CO2024000448A2 (es) Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer
CO2021009078A2 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
UY36207A (es) Inhibidores de la syk
CO2024017767A2 (es) Sales de inhibidores de sos1
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
CO2022014886A2 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
MX2025004911A (es) Terapia de combinacion para tratar el cancer
UY39819A (es) Métodos para tratar el cáncer
AR126147A1 (es) Derivados de urea para tratar el cáncer
GEAP202416416A (en) Urea derivatives which can be used to treat cancer
AR132326A1 (es) Protacs para irak4
AR132037A1 (es) Derivados de piridazinil amino como inhibidores del receptor alk5
LV15783A (lv) Jauni piruvātkināzes M2 izoformas inhibitori
AR123760A1 (es) Métodos para tratar el cáncer
AR123576A1 (es) Métodos para tratar el cáncer
CO2026001588A2 (es) Compuestos de fluoroalcoxialquileno-dihidroimidazo[5,1-d]tetrazinona y compuestos relacionados y su uso en el tratamiento de afecciones médicas
AR134695A1 (es) Protac para irak4
UY40788A (es) Compuestos para el tratamiento de trastornos neurológicos